Novavax (NASDAQ:NVAX) reported Q2 EPS of ($6.53), $12.03 worse than the analyst estimate of $5.50. Revenue for the quarter came in at $186 billion versus the consensus estimate of $1.02 billion.
GUIDANCE:
Novavax sees FY2022 revenue of $2-2.3 billion, versus the consensus of $4.27 billion.